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1. INTRODUCTION 
1.1 The ATM Gene 
DNA repair is a crucial physiological mechanism maintaining genomic DNA integrity 
in each nuclear cell. The ataxia telangiectasia mutated (ATM) protein belongs to the core 
components of DNA damage response machinery and acts as an intracellular sensor by 
recognizing DNA double strand breaks (DSB). Numerous substrates involved in DNA repair 
are regulated by ATM protein kinase activity, thereby enabling DNA breaks to be linked with 
the processes of cell cycle and/or apoptosis.  
When mutated, the ATM gene is the underlying cause of the rare autosomal recessive 
disorder ataxia telangiectasia (AT) characterized by cerebellar ataxia, oculocutaneous 
telangiectasia, immunological deficiency, hypersensitivity to ionizing radiation and 
predisposition to cancer [1]. More than 400 disease-causing mutations have been identified in 
ATM thus far and more than 70% of them result in premature termination of translation and 
truncation of the protein [2,3]. The typical AT phenotype is caused by ATM null alleles that 
either truncate (frameshift or nonsense mutations) or severely destabilize (mutations affecting 
mRNA splicing) the ATM protein [4,5]. Most mutations are unique and uniformly distributed 
throughout the gene´s open reading frame with no apparent hotspots. While the penetrance of 
truncating mutations may approach 100%, penetrance of missense mutations is lower and 
often results in a milder phenotype [6]. Usually, AT patients are compound heterozygotes; 
patients homozygous for the same mutation are rare.  
The ATM gene was mapped to chromosome 11q22-23 in 1988 [7] and cloned in 1995 
[8]. The entire gene spans almost 150 kb of the genomic DNA, consists of 66 exons and is 
transcribed in a wide range of tissues to an mRNA of approximately 13 kb with a coding 
sequence of 9168 bp. The gene encodes the 350 kDa protein containing 3056 amino acid 
residues with serine-threonine protein kinase activity [9].  
ATM and ATM and Rad3 related kinase (ATR) are thought to be master controllers of 
cell cycle checkpoint signaling pathways required for cell response to DNA damage and for 
genome stability. Besides being present in the nucleus, the ATM protein is located in the 
cytoplasm. Intracellular ATM concentration is not altered by radiation exposure but its innate 
kinase activity increases severalfold after exposure to IR [10].  
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1.2 ATM Function 
ATM is the initiator of a signaling cascade that responds to DSB. Normally, ATM is 
present in cells in the form of an inactive complex, either a dimer or a higher multimer. 
Following DNA damage, ATM undergoes autophosphorylation at S1981 leading to the 
dissociation of inactive complex and subsequent triggering of a signaling cascade involving 
phosphorylation of several substrates [11], which, in turn, results in two crucial responses to 
DNA damage: the activation of cell cycle checkpoints and the initiation of DNA repair. 
However, DNA repair failure may result in the activation of apoptosis. ATM substrates 
include p53, Mdm2 and c-Abl influencing the G1 checkpoint; NbsS1, Rad51, BRCA1 and 
Fanconi anemia complementation group D2 protein (FANCD2) involved in the transient IR-
induced S-phase arrest, and BRCA1 and checkpoint kinases 1 and 2 (Chk1, Chk2) regulating 
the G2 checkpoint [11] (see figure 1). Simultaneously, the ATM activity can be modulated by 
some of its substrates. Physiological DSB occurring during meiosis and immune system 
maturation also require ATM to initiate recombinational DNA repair. 
Figure 1: ATM is the key player in response to DNA double strand breaks. ATM can control 
cell cycle through phosphorylation of several substrates such as p53, cAbl, BRCA1 and 
Chk1/2. ATM induces DNA repair via activation of several proteins, e.g. H2AX, MRN 
complex (Mre11,Rad50, Nbs1) or BRCA1. ATM can regulate apoptosis for example through 
IκB phosphorylation. However, its role in apoptosis is not well understood. For details, see 
[12] 
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 1.3 ATM and Cancer 
During their shortened lifetime, nearly 40% of AT homozygotes develop a malignancy 
[13]. The tumor types in AT are primarily lymphomas or leukemias (approximately 85%) as 
the ATM protein in the AT individuals is unable to repair the normal DNA breakage 
generated during the immune system maturation [14]. 
The heterozygous carriers of ATM mutations account for 0.35–1% of the general 
population and their life expectancy is reduced because of an increased appearance of age-
related disorders such as ischemic heart disease [15]. With respect to the central role of ATM 
in the DNA damage response, it was expected that carriers would have an increased risk of 
various cancers. However, the elevated incidence of ovarian, lung, gastric, pancreatic, colon 
or biliary system cancers was not detected in AT families [16]. Interestingly, there is a 
correlation with ATM heterozygotes and an increase in breast cancer risk [17]. 
1.4 ATM and Familial Breast Cancer 
Breast cancer is the most common malignancy affecting western women with the 
lifetime risk of approximately 10-12%. The most significant risk factor is a family history of 
breast cancer. About 5-10% of all breast cancer cases are due to germline mutations in high 
penetrance genes. In the majority of affected families (60-80%), the disease is linked to the 
two major susceptibility genes, BRCA1 and BRCA2 [18]. Mutations in other genes such as 
Chk2 and ATM are good candidates for risk factors as well.  
The initial interest in studying ATM heterozygosity arose from epidemiological studies 
in 1991 indicating an increased risk of breast cancer in obligate AT heterozygotes from 
American families. In this study the relative risk of breast cancer in women was estimated to 
be approximately 5 times as high as in control subjects [19]. However, ATM mutation 
screening studies in cancer patients brought controversial results about the degree of the risk 
for breast cancer in heterozygous carriers of ATM mutations. In the study of Broeks et al., 
truncating germline mutations in ATM were identified in 7/82 (8.5%) Dutch patients with 
early onset breast cancer, and ATM heterozygotes had an approximately ninefold increased 
risk of breast carcinoma development [20]. Approximately twofold increase in risk of breast 
cancer was associated with ATM mutations in Britain [16,21]. Thorstenson et al. found 7 AT-
causing mutations in 230 (2.6%) high-risk breast and ovarian cancer families in Austria [22]. 
Recently, Renwick et al. concluded that women heterozygous for mutations causing AT in 
homozygotes have approximately twofold increase in risk of breast cancer development [23]. 
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 Nevertheless, many studies have failed to confirm the role of AT-causing mutations in breast 
cancer development and concluded that their contribution to familial breast cancer is minimal 
[24,25]. The studies that were focused on early onset or increased radiosensitivity breast 
cancer failed to provide evidence of increased frequency of ATM mutations compared to 
control subjects [26,27]. Other studies found a higher rate of amino acid substitutions in ATM 
in patients with breast cancer [25,28]. However, the significance of most missense variants is 
unknown and only a few of them have been considered to be pathogenic. The c.7271T>G 
transversion at the codon 2424, leading to the replacement of valine with glycine and 
consequently to the ATM protein with residual function, was associated with a mild clinical 
phenotype and lower radiosensitivity in homozygotes and increased risk of breast cancer in 
both the homozygotes and the heterozygotes [2]. The IVS10-6T>G splice site mutation 
causing the loss of exon 11 in the ATM mRNA and reduction of the full-length mRNA and 
ATM protein, is a controversial missense mutation. Broeks et al. concluded that heterozygous 
carriers of this mutation have an increased risk of breast cancer development characterized by 
increased occurrence of bilateral cancer and early age at onset [29]. However, Szabo et al. 
reported that IVS10-6T>G did not confer an elevated risk for breast cancer [30]. 
It has been proposed that heterozygotes with the truncating type of mutations and 
those with missense mutations can exhibit distinct cancer risk as both types of mutations can 
exert variant effects on ATM function. Little or no protein, even a shortened form, is 
produced from the allele with the truncating type of mutation. On the other hand, alleles with 
the missense type of mutation express an ATM protein, albeit of a mutant form. According to 
this hypothesis, the truncating mutations act in recessive fashion whereas most missense 
mutations may act in a dominant fashion [6]. Funtional assays are necessary to evaluate the 
true significance of particular mutations in breast cancer development. 
It has been shown in vitro that cells heterozygous for AT-causing mutations are more 
sensitive to radiation [31]. Additionally, irradiated mice heterozygous for ATM mutations had 
an increased frequency of dysplastic breast cells, supporting an increased cancer risk for 
heterozygotes that is related to their mutagene exposure [32]. The consequences of these 
studies are not merely academic as a common treatment regime for breast cancer involves 
radiotherapy. Paradoxically, could part of the cure exacerbate the disease in breast cancer 
patients who are ATM heterozygous? Also mammography involves irradiation, so could 
breast screening provoke breast cancer development in ATM heterozygous women? So far, 
human studies with small numbers of patients have not found a correlation between 
hyperradiosensitivity in breast cancer patients treated by radiotherapy and mutations in the 
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 ATM gene [20], but much more research is needed. Until it has been proven safe, perhaps 
non-radiation techniques for the early detection of breast cancer, such as sonography or 
magnetic resonance imaging, should be used and radiotherapy given as a last resort in ATM 
heterozygotes. 
1.5 ATM and Sporadic Breast Cancer 
Breast cancer is a malignancy with numerous genetic alterations. The classical 
Knudson´s two hit hypothesis predicted that a phenotypic manifestation of tumor-suppressor 
gene inactivation is undetectable unless the two alleles of a single gene are inactivated. 
Alleles of tumor-suppressor genes can be lost or inactivated in a variety of ways during 
tumour development, ranging from chromosomal deletions, insertions or rearrangements to 
single base mutations or epigenetic promoter alterations such as DNA hypermethylation. 
Tumor-suppressors often reside in genomic regions characterized by frequent 
chromosomal deletions, which cause loss of heterozygosity (LOH). Generally, the 
background rate of allelic deletions reaches up to 5% [33]. However, deletions of ATM alleles 
are much more common in breast tumors indicating the important role of the gene in breast 
cancer development. Numerous studies identified allelic losses in nearly 40% of sporadic 
breast cancer cases and suggested that LOH in the ATM locus may occur early in breast 
tumorigenesis [33,34]. Nevertheless, the process of the second allele inactivation often 
remains unidentified. Some findings indicated that haploinsufficiency at ATM may promote 
tumorigenesis due to the increased chromosomal instability, even though LOH identification 
at the ATM loci supported the more classic two-hit tumor-suppressor gene model [35]. In 
recent epidemiologic studies, no somatic mutations were found in mammary carcinomas from 
midwestern United States and Japan [36]. Thus, it seems that inactivation of the ATM gene by 
somatic mutations is not a common hallmark of breast cancer. Similar results were obtained 
from BRCA1/2 studies, where acquired somatic mutations rarely occur in these major breast 
cancer susceptibility genes [37].  
Another mechanism contributing to the loss of a tumor-suppressor function is the 
methylation of cytosine residues located within the CpG islands. These commonly 
unmethylated dinucleotide regions are clustered in the proximal promoters of almost half of 
the genes in the human genome [38]. Promoter hypermethylation often results in an 
inappropriate transcriptional silencing of nearby genes and is at least as common as the 
disruption of classic tumor-suppressor genes in human cancer by mutations [38]. In cancer, 
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 many key tumor-suppressor genes, including BRCA1 and E-cadherin, are subjected to this 
epigenetic silencing, which is now widely recognized as a causative or correlative event in 
tumor development. Nearly 50% of the tumor-suppressor genes associated with rare inherited 
cancer syndromes are known to undergo methylation of their promoters in sporadic cancer 
[38]. Numerous studies demonstrated the hypermethylation as a second inactivating event in 
tumors in patients carrying germline mutations in tumor-suppressor genes. Interestingly, 
methylation seems to be always associated with the wild-type allele [38].  
ATM is transcribed from a bidirectional promoter. The 520 bp intergenic region is 
shared with the NPAT gene. NPAT protein is a substrate of cyclin E-Cdk2 kinase and is 
thought to play an important role in a coordinated transcriptional activation of histone genes 
during the G1/S phase transition and in S phase entry in mammalian cells [39]. Nevertheless, 
the ATM promoter methylation was found not to influence the NPAT gene expression [40]. 
The epigenetic silencing of ATM expression was described once in locally advanced breast 
tumors suggesting a link between reduced ATM function and sporadic breast cancer [41]. 
However, other studies did not reveal hypermethylation of ATM promoter in any of tested 
breast tumor samples [42,43] 
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2. AIMS OF THE STUDY 
 
The aim of this study was to analyze the ATM gene in breast cancer including the 
design and optimalization of particular methods. The study was focused on the following 
parts: 
 
1. The role of the ATM gene in hereditary breast cancer 
• Mutation analysis of the ATM gene in high-risk breast cancer patients 
• Analysis of breast tumor tissue gained from patients carrying mutation     
                        in the ATM gene 
2. The role of the ATM gene in sporadic breast cancer 
• Loss of heterozygosity analysis in sporadic breast cancer  
• Mutation analysis of the ATM gene in sporadic breast cancer 
• Detection of ATM promoter hypermethylation in sporadic breast cancer 
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3. MATERIALS AND METHODS 
3.1 Material 
3.1.1 Hereditary breast cancer 
EDTA blood samples were collected from high-risk breast cancer patients at the 
Department of Oncology and at the Department of Gynecology and Obstetrics of the First 
Faculty of Medicine of Charles University in Prague. A total of 114 patients were selected 
from families with two cases of breast cancer diagnosed before the age of 50 or three or more 
cases of breast (or ovarian) cancer diagnosed at any age. Genetic testing was further offered to 
patients diagnosed with breast cancer before the age of 40 (42 women) or with bilateral breast 
cancer before the age of 50 (5 women), regardless of family history of cancer. The paraffin-
embedded tumor samples from ATM mutation carriers were obtained from the Institute of 
Pathology of the First Faculty of Medicine. Control blood samples were obtained from 
random blood donors of mixed gender. All women in the study gave signed informed consent 
prior to genetic testing. The protocol of investigation was approved by the Ethical Committee 
at the First Faculty of Medicine. 
3.1.2 Sporadic breast cancer 
73 nonselected sporadic tumors paired with EDTA blood samples were collected at the 
Department of Oncology and at the Department of Gynecology and Obstetrics of the First 
Faculty of Medicine of Charles University and General Teaching Hospital in Prague . All 
tumors were histologically confirmed and analysed for grading, estrogen (ER) and 
progesteron (PR) receptors, c-ErbB-2, Ki-67 and proportion of cancer cells. 
3.1.3 DNA and RNA isolation 
Genomic DNA was isolated from blood samples using the Wizard Genomic DNA 
Purification Kit (Promega) and from tumor samples using the QIAamp DNA Mini Kit 
(Qiagen). Total RNA from frozen tissue was isolated using RNeasy Mini Kit (Qiagen) 
according to the manufacturer´s instructions. Total RNA from peripheral blood lymphocytes 
was purified by acid guanidinium thiocyanate- phenol-chlorophorm extraction [44] and 
reverse-transcribed into cDNA using random hexamers according to the manufacturer’s 
protocol (Roche).  
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 3.2 Mutation analysis 
Mutational screening, based on RNA-analysis, included amplification of the entire 
coding sequence of the ATM gene, pre-screening of mutations by the protein truncation test 
(PTT) and their characterization by direct DNA sequencing. The coding region of ATM was 
divided into 7 overlapping fragments and amplified from cDNA by the polymerase chain 
reaction (PCR). Amplifications were performed in 10 µl reaction mixtures containing 1 µl of 
PCR buffer (Roche Molecular Biochemicals), 0.2 mM of each dNTP, 0.4 µM of each primer, 
1 µl of cDNA template and 0.5 U of Fast Start Taq DNA polymerase (Roche). Following 
initial denaturation (at 95º C for 6 min), 35 cycles (at 95ºC for 30 sec, 58ºC or 62ºC for 30 sec 
for individual fragments, and 72ºC for 2 min) and final extension (at 72ºC for 7 min) were 
performed. PCR products were analyzed on 1.5% ethidium bromide-stained gels. Primer 
sequences were taken from Telatar et al. [45]. From each sample, 1 µl of the PCR product 
was incubated in the TnT/T7 coupled transcription/translation system (Promega) 
supplemented with [35S]methionine (Amersham Biosciences) following the manufacturer’s 
protocol and translated proteins were then separated on 12% SDS-polyacrylamide gels. After 
electrophoresis, gels were fixed, washed in fluorographic solution (Amplify, Amersham 
Biosciences), dried and exposed to X-ray film at -80°C. PCR products that gave rise to 
truncated proteins by PTT-analysis were purified and directly sequenced using the BigDye 
terminator cycle sequencing kit version 3.1 in a model AbiPrism 310 or 3130 automated DNA 
sequencer (Applied Biosystems). Mutations were confirmed by nucleotide sequence analysis 
of DNA samples.  
The nomenclature of mutations used is according to den Dunnen and Paalman [46], 
with nucleotides numbered from the A of the ATG initiation codon of GenBank reference 
sequence U33841 for the complete ATM cDNA. Original designations for ATM mutations 
commonly referred to in the literature are included for ease of cross-referencing. 
3.3 Analysis of splicing products in tumors with ATM germline mutation 
To specify precisely the effect of IVS10-6T>G, IVS36+1A>G and c.6096-9delTTCTT 
mutations detected in high-risk breast cancer patients on splicing, we analyzed RNA samples 
extracted from peripheral blood of heterozygous mutation carriers and control healthy 
individuals. Individual cDNA samples obtained by reverse transcription served as templates 
for PCR-amplification using primers flanking either exon 11 (5´-
GATCTGCTAGTGAATGAGATAAGTC-3´ - forward and 5´-AATGCAACTTCCGTAAGGC-3´ - 
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 reverse) or exon 36 (5´-CCATTGACAAGACTTGAAGGACT-3´ - forward and 5´-
GCTGTAGATAGGCCAGCATTG-3´ - reverse) or exon 44 (5´-
CAGAAGTATAGGGGAGCCAGATAG-3´ - forward and 5´-CTGACGGAAGTGCAATGGT-3´ - 
reverse). PCR reactions were performed in 27 cycles (annealing at 60ºC, 58ºC and 64ºC, 
respectively); other reaction conditions and cycling parameters were as described above. The 
forward primers were fluorescently labeled with 6-FAM. The PCR products were separated in 
an ABI 3130 automated DNA sequencer and relative quantities of the full-length products and 
the products lacking the respective exon were determined by GeneMapper Software Version 
4.0 (Applied Biosystems). 
3.4 Immunohistochemistry 
Paraffin sections obtained from tumor-tissue or metastasis of heterozygous mutations 
carriers as well as from sporadic tumors were used for histological and immunohistochemical 
examination. The mouse monoclonal antibody ATM Ab-8 (clone ATX08) (Neomarkers – Lab 
Vision Corporation) specific to the C-terminus of ATM was used for the detection of the 
protein according to the manufacturer’s instructions. 
3.5 LOH analysis 
Paired samples of lymphocyte and tumor DNA served for LOH analysis carried out 
for three microsatellite markers; one (D11S2179) intragenic to ATM and two (D11S1819, 
D11S1294) that flank this gene on the centromeric and telomeric side, respectively. Primer 
sequences for microsatellite marker loci were retrieved from the Genome Database 
(http://www.gdb.org). PCR reactions of 10 µl volume contained 0.5 U of TaqDNA 
polymerase (Finnzymes) and 20-50 ng of DNA. Amplification was carried out under the 
following conditions: denaturation at 93°C for 3 min; 35 cycles of 93°C for 30 sec, 55°C, 
60°C or 65°C (for D11S1294, D11S1819 and D11S2179, respectively) for 30 sec and 72°C 
for 30 sec; final extension at 72ºC for 5 min. PCR products were analyzed either on precast 
Spreadex gels or on automatic sequencer AbiPrism3130. 
3.5.1 Electrophoresis on precast Spreadex gels 
PCR products were run on precast Spreadex gels using SEA 2000 electrophoretic 
apparatus (Elchrom Scientific) and visualized by SYBR Gold Nucleic Acid Gel Staining 
(Invitrogen) according to manufacturer’s instructions. The ElQuant software (Elchrom 
Scientific) was used for choosing an appropriate gel and electrophoretic conditions. Two-fold 
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 or greater reduction in the relative allele intensity ratio measured between tumor and normal 
DNA was indicative of LOH for a given marker. Assessment of allele loss was accomplished 
by two independent observers. 
3.5.2 Electrophoresis on AbiPrism 3130 
Prior this analysis, the PCR products were amplified using forward primers labelled on 
5´end by 6-FAM. 0.5 µl PCR product was mixed with 9.3 µl HiDi formamide and 0.2 µl size 
standard LIZ-600 (Applied Biosystems) and denaturated. Elektrophoresis was performed 
under denaturing conditions in the 36 cm capillary filled with POP-7 polymere on Abi Prism 
3130 (Applied Biosystems). GeneMapper, v4.0 (Applied Biosystems) was used for the LOH 
assessment. 
3.6 Promoter methylation analysis 
Hypermethylation of ATM promoter was analysed by bisulfite sequencing and 
methylation specific multiplex ligation-dependent probe amplification (MS-MLPA). 
3.6.1 Bisulfite sequencing 
The DNA isolated from tumor tissue was analyzed for the cytosin methylation status 
of the ATM promoter by bisulfite sequencing. DNA samples (0.5 µg of each) were modified 
by bisulfite using EZ DNA Methylation-Gold kit (Zymo Research) following the 
manufacturer’s protocol. CpGenome Universal Methylated DNA (Intergen) was used as a 
positive control. The PCR mixture contained 1x PCR Gold Buffer, 2 mM MgCl2, 0.4 mM of 
each dNTP, 0.4 µM of each primers (5´-TTTTTAGATTTGGAGGGG-3´ - forward and 5´-
CCCACTTCTAAAAAAAAAAA-3´ - reverse), 2 µl of bisulfite-modified DNA and 0.625 U 
of hot-start AmpliTaq Gold polymerase (Applied Biosystems) in a total volume of 25 µl. 
Amplification was performed under the following conditions: 95°C for 10 min and 40 cycles 
of 95°C for 30 sec, 52°C for 30 sec and 72°C for 40 sec. The PCR products were directly 
sequenced using the forward primer and the BigDye terminator cycle sequencing kit version 
3.1 in a model AbiPrism 3130 automated DNA sequencer (Applied Biosystems).  
3.6.2 MS-MLPA 
Two kits - MS-MLPA ME001 and ME002 (MRC Holland) together with methylation 
sensitive endonuclease HhaI (Promega) were used for detection of the ATM promoter 
methylation. Amount of 90 ng of tumor DNA was used as a template. CpGenome Universal 
Methylated DNA served as a control (Intergen). Reactions were performed in half volume 
according to the manufacturer´s instructions (for further information see www.mlpa.com). 
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 Electrophoresis was performed under denaturing conditions in the 36 cm capillary filled with 
POP-7 polymere on Abi Prism 3130 (Applied Biosystems). Promoter methylation was 
connected with presence of corresponding peak and was quantified through comparison of 
ratio between tested peak and sum of control peaks in reaction with and without added HhaI 
nuclease. Methylation higher than 10% was assessed as abberant [47]. 
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4. RESULTS AND DISCUSSION  
4.1 ATM and hereditary breast cancer 
In our study, pathogenic mutations in ATM were detected in 3 (1.9%) out of 161 high-
risk breast cancer patients not related to BRCA1/2 whereas none mutation was identified in 
183 controls. Two detected pathogenic mutations were splicing variants resulting in a shift of 
the ATM reading frame and premature termination of translation. The incidence of truncating 
mutations predominating in AT was comparable to that ascertained in UK (9/443, 2.0%) [23] 
and Austria (4/270, 1.5%) [22]. In addition, we detected the splicing variant c.1066-6T>G 
once among affected individuals (1/161; 0.6%) and twice among controls (2/183; 1.1%) 
(Tables 1 and 2). To investigate the effect of mutations intervening in splicing, we performed 
quantitative analyses of RNA samples obtained from breast cancer patients carrying the 
respective mutations in ATM and from unaffected healthy individuals.  
 
Table 1. Frequencies of ATM mutations in relation to the classification of patients 
Classification No of patients/controls
No. of mutations exluding 
c.1066-6T>G (%) 
c.1066-6T>G 
(%) 
Breast cancer patients    
   from HBC/HBOC families 114 2 (1.8) 1(0.9) 
   without family history of breast cancer    
        bilateral breast cancer before 50 5 0 (0) 0 
        breast cancer before 40 42 1 (2.4) 0 
Total 161 3 (1.9) 1 (0.6) 
Controls 183 0 2 (1.1) 
HBC, hereditary breast cancer; HBOC, hereditary breast and ovarian cancer 
 
The c.5932G>T nonsense mutation that leads to the termination of translation at codon 
1978 had previously been shown as causative in AT [5]. The mutation c.6096-9delTTCTT 
(IVS43-9del5), described in AT patients, causes skipping of the adjacent exon 44 as a result 
of the disturbance of the polypyrimidine tract close to the 3´splice site [5]. The c.5177+1G>A 
(IVS36+1G>A) mutation affects the 5´splice site, which results in the aberrant splicing and 
loss of exon 36. Quantitative analysis showed that the shortened transcript with the loss of 
exon 36 represented 53.6% of the ATM transcripts on average in a heterozygous carrier of this 
mutation. Similar results of RNA analysis (47.2% of the spliced transcript lacking exon 44 on 
average) were obtained in a carrier of the splicing mutation c.6096-9delTTCTT that was 
confirmed to cause AT. No transcripts lacking exon 36 or 44, respectively, were observed in 
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 controls. Presented data indicate that the c.5177+1G>A mutation can be predicted to cause 
AT. 
The c.1066-6T>G (IVS10-6T>G) splicing variant also affects the highly conserved 
polypyrimidine region and leads to incorrect splicing and loss of exon 11. The substitution has 
previously been identified in a number of breast cancer patients, however only once in an AT 
patient in homozygous state [29]. In the study of Szabo et al.[30], similar frequencies of the 
c.1066-6T>G mutation were found in a group of breast cancer families from diverse 
geographical regions obtained from five centers (8/961; 0.8%) and in a group of control 
individuals (4/543; 0.7%). Neither Bernstein et al. found an association between c.1066-
6T>G and breast cancer [48]. In our study, incorrect splicing and loss of a small proportion of 
exon 11 (6%-15%) was also detected in control individuals without the c.1066-6T>G 
mutation in both lymphocytes and breast tissue. Presented results suggest that the variant 
c.1066-6T>G does not confer an elevated breast cancer risk. On the other hand, individuals 
heterozygous for the c.1066-6T>G variant displayed loss of exon 11 in 47%-57% of ATM 
transcripts. Likewise, there is a discrepancy in pathogenicity of the c.1066-6T>G variant with 
respect to AT. Despite the high population frequency, this variant has been identified only in 
one patient with AT who was homozygous for this gene alteration. However, this patient 
exhibited all typical symptoms of classical AT and quantitative analysis performed in 
lymphoblastoid cell line established from this patient detected the loss of exon 11 in 93% of 
ATM transcripts [28]. 
 
Table 2. ATM mutations identified in high-risk breast cancer patients 
Family No Mutation ∗ Predicted effect Diagnosis(age) Cancers in family (age at onset) 
410 c.5177+1G>A Exon 36 skipped, ter 1680 Bilateral breast cancer (42, 44) 
Pancreatic (75), breast (64), 
breast (?) 
116 c.5932G>T  E1978X Bilateral breast cancer (53,60), ovarian cancer (61) 
Ovarian (57), leukemia (?), 
kidney (?), lung (59) 
96 c.6096-9delTTCTT Exon 44 skipped, ter 2032 Breast cancer (37) Pancreatic (73) 
69 c.1066-6T>G Exon 11 skipped,  ter 372 Breast cancer (32) Breast (60), breast (?) 
∗ Position in cDNA is according to GenBank accession no. U33841; +1 corresponds to the A of the 
ATG translation initiation codon  
 
Bilateral breast cancer and a strong family history of cancer occurred in two patients 
with the c.5177+1G>A and c.5932G>T truncating mutations. Other patient carrying the 
c.6096-9delTTCTT alteration was diagnosed with breast cancer before the age of 40. The 
patient with the c.1066-6T>G mutation developed breast cancer at the age of 32 and two other 
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 members of the family were also affected with this malignancy (Table 2). DNA samples for 
genotyping were available only in one affected person in each family. 
Cells from obligate AT heterozygotes display increased chromosomal instability and 
have been shown to exhibit elevated radiosensitivity, which suggests that haploinsufficiency 
at the ATM locus may promote tumorigenesis [49,50]. On the contrary, high frequency 
(~40%) of allelic losses at the ATM region in sporadic breast tumors rather supports the 
classical Knudson’s two-hit hypothesis [34]. Nevertheless, the process of inactivation of the 
retained allele remains poorly characterized. The paraffin-embedded tumor samples were 
obtained from 3 ATM heterozygotes. Tumor tissue was not available in the patient carrying 
the c.5177+1G>A mutation. In a carrier heterozygous for the c.1066-6T>G mutation, DNA 
was isolated from metastasis whereas in other two patients from primary tumors. The ATM 
mutations identified in peripheral blood were confirmed in each of the tumor samples.  
Immunohistochemical analysis proved loss of expression of ATM protein in all 
accessible tumor samples from heterozygous mutation carriers, including the sample 
heterozygous for c.1066-6T>G mutation. In a parallel analysis, breast carcinomas from 
patients without the ATM mutation expressed high level of the ATM protein. To analyze the 
process of gene inactivation more precisely, we examined tumor samples for LOH at the ATM 
locus and for methylation of CpG islands of the ATM promoter. However, none of the tumors 
from heterozygous mutation carriers displayed LOH at this locus. Accordingly, it seems that 
the loss of the wild type ATM allele is not a common event in breast tumorigenesis. 
Alternative way of gene inactivation includes promoter hypermethylation. However, our 
analyses detected hypermethylation of ATM promoter only in a carrier heterozygous for the 
c.1066-6T>G mutation. In this tumor samples, MS-MLPA revealed hypermethylation in 21 
out of 27 tested CpGCpG dinucleotides of 25 different promoters including ATM. Together 
with the fact that the DNA was isolated from metastasis, we concluded that hypermethylation 
of ATM in this sample is not causal and is probably connected with the advanced disease. 
Hypermethylation can result from overexpression of de novo DNA methyltransferases 
common in cancer [51,52] leading to genome instability. 
4.2 ATM and sporadic breast cancer 
In our group of 73 sporadic breast carcinomas, we analyzed ATM inactivation by loss 
of heterozygosity, somatic mutation and promoter hypermethylation. 
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 4.2.1 Loss of heterozygosity 
For LOH evaluation, three microsatellites with high heterozygosity (80.6-97.6%) in 
the ATM locus were analyzed. Only one sample was not informative (1.4%). LOH in the ATM 
locus was found in 20.8% samples, which is less than in BRCA1 (22.7%), BRCA2 (26.7%) 
and TP53 (34.8%) loci [37]. Frequency of LOH in ATM is considerably higher than 5%, 
which is thought to be the likelyhood of random allele loss [33]. These results indicate that 
ATM has a role in sporadic breast cancer tumorigenesis. LOH in ATM was uniformly 
distributed among all histological tumor types as well as in tumors of various 
immunohistochemical characteristics except protein c-ErbB-2 expression. Interestingly, none 
of tumors carrying LOH in ATM expressed c-ErbB-2 protein whereas in our group only 
65.8% of tumors were c-ErbB-2 negative. However, the relationship between c-ErbB-2 and 
ATM proteins is unknown.  
The LOH data were further analyzed using TIGR MultipleExperimentViewer v.4.0 
software (available on 
http://www.tigr.org/software/tm4/menu/TM4_Biotechniques_2003.pdf) [53]. The clustering 
analysis showed that LOH in BRCA1 and BRCA2 are associated and together with LOH in 
TP53 make up one cluster whereas LOH in ATM represents another group. Thus, it seems that 
BRCA1, BRCA2 and TP53 tumor-suppressor genes take part in one tumorogenic pathway 
whereas ATM in different one. 
4.2.2 Mutation analysis 
We screened the entire ATM open reading frame for pathogenic mutations in tumors 
with LOH in this locus using PTT. No somatic mutation was identified in the group of 15 
tumors with ATM allelic loss. 
Somatic mutations were not detected in ATM in sporadic breast cancer so far and thus, 
similarly to BRCA1/2 [37], are considered as rare. Nevertheless, low frequency of somatic 
mutations can be caused by the fact that the vast majority of studies was dealing with 
mutation analysis in hereditary breast cancer. 
4.2.3 Promoter methylation analysis 
ATM promoter methylation was detected in none out of 71 analyzed sporadic breast 
carcinomas (bisulfite sequencing, MS-MLPA). To date, three studies have been dealing with 
ATM methylation. Vo et al. identified hypermethylation of 78% of 23 breast cancer cell lines 
[41]. On the other hand, neither Treilleux et al. [42] (74 sporadic breast carcinomas) nor 
Allinen et al.  [43] (30 tumors) have found ATM promoter methylation. 
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 We also analyzed promoter methylation in other tumor-suppressor genes by MS-
MLPA. With respect to breast cancer predisposition genes, BRCA1 promoter was methylated 
in 3 samples and TP53 in 2 cases. Similarly to ATM, BRCA2 methylation was not detected in 
any tested tumor. These results show that hypermethylation of genes involved in pathogenesis 
of hereditary breast cancer is in sporadic cancer rather uncommon. 
Concerning other analyzed genes, the most frequently methylated promoters were 
CDKN2B (cyclin-dependent kinase inhibitor 2B) (89%), WT1 (Wilms tumor 1) (79%), PAX5 
(69%) and RASSF1 (Ras-associated domain family 1) (2 probes, 69 and 70%). CDKN2B 
codes for p15 protein which inhibits G1 phase of cell cycle through inhibition of cyclin 
dependent kinases Cdk4 and/or Cdk6. Methylation of this gene has been described once in 2% 
(2/105) of sporadic breast carcinomas [54]. However, we detected considerably higher 
proportion of samples with this gene´s promoter methylation (89%). RASSF1 tumor-
suppressor gene encodes a protein, related to Ras protein, inhibiting cyclin D1 accumulation, 
which, in turn, leads to cell cycle arrest. RASSF1 methylation is a frequent event in cancers, 
particulary in early stage of carcinomas development [55,56]. WT1 codes for a transcription 
factor acting as either activator or repressor of many genes. Depending on the rate between 
expressed isoforms, the breast malignant phenotype can be either enhanced or suppressed 
[57]. Similarly, PAX5 also encodes a transcription factor which plays a role in cell 
differentiation and embryonic development [58]. WT1 hypermethylation has not been 
identified so far whereas PAX5 hypermethylation was detected in approximately 65% of 
breast carcinomas, which is consistent with our findings [58]. 
Generally, the samples were methylated in 7 tested dinucleotides CpGCpG on average 
(median = 7, arithmetic mean = 7,43). Currently, it is not known methylation of which CpG 
dinucleotides of particular genes leads to significant decrease or eventually to complete 
transcription silencing. Therefore, this study will be followed by expression analysis of genes 
with aberrant promoter methylation by real-time PCR. 
4.2.4 Immunohistochemistry 
The ATM protein was immunohistochemically analyzed in all available samples (46 
sporadic breast tumor tissues). ATM expression was decreased in almost all tested samples. 
However, the lower expression was not associated with LOH. 
4.2.5 The ATM gene inactivation 
In our group of sporadic breast carcinomas, we detected LOH in the ATM locus in 
20,8% cases. In addition, neither somatic mutation nor promoter hypermethylation was 
detected in any analyzed sample. However, the immunohistochemical analysis found 
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 decreased amount of the ATM protein in almost all tumors. Similarly, other studies described 
lower amount of ATM protein in high proportion of sporadic breast carcinomas (~75%) 
[42,59]. It was showed that decreased ATM transcription might be caused by lower 
expression of the DNA-PK protein (a protein kinase which takes part in DSB repair through 
the mechanism nonhomologous end joining) but a mechanism of such positive regulation is 
uncertain. Generally according to results of many studies, it can be sum up that expression 
changes of genes involved in DSB repair are associated with breast cancer pathogenesis 
[42,59]. 
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5. CONCLUSIONS  
 
Incidence of breast cancer is continuously increasing in the Czech Republic. Tumor 
development is a result of gene alterations´accumulation, particulary associated with genes 
involved in regulation of cell growth and division. Hereditary carcinomas account for 
approximately 5-10% of all breast tumors and in 60-80% cases are caused by a germline 
mutation in the major predisposition genes BRCA1 and BRCA2. Nevertheless, other genes, 
mostly of lower penetrance, may play a role in breast pathogenesis such as the ATM tumor-
suppressor gene.  
ATM is the apex of the repair pathway of DSB. This protein kinase activates through 
phosphorylation of its substrates cell cycle checkpoints, which leads either to the delay of the 
cell cycle progression until DSB are repaired or to the promotion of apoptosis.  
The aim of our study was to establish the ATM mutations frequency in high-risk breast 
cancer patients in our population and specify this gene´s alterations in sporadic breast cancer. 
That included design and optimalization of method for mutation analysis, loss of 
heterozygosity detection and methods for detection of ATM promoter hypermethylation. 
Our results suggest that truncating mutations in ATM that occur in AT contribute in 
heterozygous carriers to the breast cancer development and the splicing variant c.1066-6T>G 
is not associated with hereditary breast cancer with respect to the occurrence in population. 
Absence of the ATM protein in all available tumor samples of heterozygous mutation carriers 
indicates that complete loss of this protein may be required for tumorigenesis. However, the 
precise mechanism of the second allele inactivation remains obscure.  
Concerning the role of ATM in sporadic breast tumorigenesis, we analyzed loss of 
heterozygosity, promoter methylation and somatic mutations in a group of sporadic breast 
carcinomas. High frequency of LOH indicates that ATM is involved in nonhereditary breast 
carcinomas development. However, we found neither promoter methylation nor somatic 
mutation in any tumor sample. 
To sum up, the ATM gene seems to have a role in breast cancer development in a 
minority of the high-risk families in our population which is significantly lower compared to 
BRCA1/2 and it also seems to be involved in pathogenesis of sporadic breast cancer. Despite 
the ATM gene´s length, we do not perform the preventive screening of this gene in breast 
cancer high-risk families. Nevertheless, we offer the molecular diagnostics of ATM to ataxia 
telangiectasia patients. 
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